HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Highlights Work To Advance Predictive Toxicology, Non-Animal Testing For Cosmetics

Executive Summary

The FDA’s cosmetics office is exploring integrated testing strategies to identify potential skin sensitizers without use of animals, as well as use of in vitro assays to evaluate cosmetic ingredients’ dermal penetration potential. Meanwhile, CFSAN is testing the effects of substances on gene expression in collaboration with other federal agencies as part of Tox21-Phase III.

You may also be interested in...



FDA: Scientific Progress Still Needed To Support Cosmetic Animal Testing Ban

The US FDA is highly engaged in the areas of predictive toxicology and alternative methods to phase out cosmetic animal testing, including evaluation of a 3D-bioprinted human skin model for in vitro permeation testing. However, continued progress is “critically needed” to make feasible the ban on cosmetic animal testing envisioned by US lawmakers, agency leadership suggests.

Cosmetics Sector Needs Positive, Not Punitive, 21st Century Regulation – IBA

Independent Beauty Association president Ken Marenus discusses the trade group’s vision for modern, proportionate cosmetics regulation and forces at work that could undermine progress and endanger small businesses.

US Humane Cosmetics Act Backed By Industry And NGOs Alike; Here’s Why

The proposed bill in the US Senate could be seen as slightly friendlier to the cosmetics industry when it comes to continued use of animal testing data in limited, exempted contexts, compared with similar state laws enacted of late. But the federal bill includes stiffer penalties, addresses “cruelty free” labeling, and seeks to spur FDA acceptance of alternative test methods, a key objective for stakeholders overall.

Related Content

Topics

UsernamePublicRestriction

Register

RS151416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel